Genzyme, a Sanofi company, announced that the European Commission has granted marketing authorization for Aubagio 14 mg, a once-daily, oral therapy indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. The EU approval of Aubagio was based on data from the Phase III TEMSO and TOWER trials. In these trials, Aubagio significantly reduced the annualized relapse rate and the time to disability progression at two years versus placebo.
- Pharmaceuticals & Drug Trials
- European Commission